Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp).

ESMO Open · 2022 · PMC8685988 · PMID 34922298

Europe PMC DOI

hedged sentence

0.4200

closest p · 8.4× alpha

0.4200

boldest claim

The sentences

did not reach statistical significanceP = 0.42not close (p > 0.1)

Efficacy The ORR was 9.4% with varlitinib plus capecitabine and 4.8% with placebo plus capecitabine, but the difference did not reach statistical significance (odds ratio 2.28; 95% CI 0.46-14.76; P = 0.42; Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.